Adagene is a clinical-stage company developing masked antibody therapies using its SAFEbody technology. Its lead program is muzastotug, which it is testing in combination with Merck (NYSE:MRK)'s Keytruda, or pembrolizumab, in microsatellite stable colorectal cancer, a form of the disease that has historically responded …
The company published no press release, regulatory update or analyst action dated November 12 or 13. Its latest substantive news was the third-quarter 2026 report, covered in a November 4Earningsanalysis, more than a week before this session.
The company published no announcement for the session, so the fall came against the stock's short trading history and Friday's weak market backdrop.
Clinical-stage biotech names like Candel are inherently binary and sentiment-driven. Their value rests on expectations about programs still working their way through development and toward regulatory milestones, and the company is advancing toward a year-end biologics license application filing for a prostate cancer therapy. …
CVS Health (NYSE:CVS) had a good quarter and a bad day. On November 4th it reported adjustedEarningsof $2.09 a share, against the $1.65 analysts expected. It raised its 2026 forecast to at least $8.20 and guided to at least $8.65 for 2027, ahead of …
Key HighlightsLifeMD (NASDAQ:LFMD) traded at USD 2.31 intraday on November 13, 2026, up 39.27%, on about 2.69 million shares, more than three times its averageVolumeof about 784,000.Third quarterRevenuewas USD 44.6 million, down about 7% and below guidance, and full year 2026 revenue guidance was …
Key HighlightsDataMEDS AI (NASDAQ:MEDS) traded at USD 0.92 intraday on November 13, 2026, up 6.24%, with aMarket Valueof about USD 4.74 million, near its 52-week low of USD 0.82.The company reported a third quarter net operating profit of about USD 10.5 million against a …
Key HighlightsPrime Medicine (NASDAQ:PRME) traded at USD 4.22 intraday on November 13, 2026, up 8.49%, giving aMarket Valueof about USD 766 million.Third quarterRevenuerose to about USD 4.2 million from about USD 1.2 million, and the net loss narrowed to USD 39.0 million, or USD …
Key HighlightsLucid Diagnostics (NASDAQ:LUCD) traded at USD 0.45 intraday on November 13, 2026, up 8.14%, with aMarket Valueof about USD 85.9 million.Medicare now pays a national rate of USD 1,938.01 per EsoGuard test from October 2026, and October testVolumeexceeded 1,800.Third quarterRevenuewas flat at about …
Key HighlightsCerenome (NASDAQ:CNSY) traded at USD 1.10 intraday on November 13, 2026, up 42.76%, on about 1.37 million shares, roughly twice its average volume, with aMarket Valueof about USD 8.24 million.Interim results from the first ten patients in a multidose trial of REYOBIQ in …